MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS

MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS

LA JOLLA, Calif., April 15, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical comp...
read more
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) &#...
read more
Insurers’ denials of opioid coverage spurs CDC to clarify guidelines

Insurers’ denials of opioid coverage spurs CDC to clarify guidelines

(HealthDay)—People with severe pain from cancer ...
read more
Gabapentin and pregabalin become class C drugs

Gabapentin and pregabalin become class C drugs

An expert in mental health and addiction at the Un...
read more
Four-to-seven-day opioid Rx likely sufficient for acute pain treatment

Four-to-seven-day opioid Rx likely sufficient for acute pain treatment

(HealthDay)—An opioid supply for seven or fewer ...
read more
What pill is that? Cheap and easy pill testing could soon be in your own hands

What pill is that? Cheap and easy pill testing could soon be in your own hands

Almost nine out of ten Australians take some form ...
read more
Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

MORRIS PLAINS, N.J., Feb. 20, 2019 (GLOBE NEWSWIRE...
read more
Study finds rise in overdoses from opioids in diarrhea drug

Study finds rise in overdoses from opioids in diarrhea drug

A Rutgers study has uncovered a new threat in the ...
read more
9 Medications That Can Interfere With Your Workout

9 Medications That Can Interfere With Your Workout

Here’s a list of nine drug classes you should be...
read more
New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder

New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder

PARIS, Jan. 9, 2019 /PRNewswire/ — The New E...
read more